Pathologic features of down syndrome myelodysplastic syndrome and acute myeloid leukemia a report from the Children’s Oncology Group protocol AAML0431

Kelley J. Mast, Jeffrey W. Taub, Todd A. Alonzo, Alan S. Gamis, Claudio A. Mosse, Prasad Mathew, Jason N. Berman, Yi Cheng Wang, Heath M. Jones, Dario Campana, Elaine Coustan-Smith, Susana C. Raimondi, Betsy Hirsch, Johann K. Hitzler, David R. Head

Research output: Contribution to journalArticle

Abstract

Context.—Detailed diagnostic features of acute myeloid leukemia in Down syndrome are lacking, leading to potential misdiagnoses as standard acute myeloid leukemia occurring in patients with Down syndrome. Objective.—To evaluate diagnostic features of acute myeloid leukemia and myelodysplastic syndrome in patients with Down syndrome. Design.—Diagnostic bone marrow samples from 163 patients enrolled in the Children’s Oncology Group study AAML0431 were evaluated by using central morphologic review and institutional immunophenotyping. Results were compared to overall survival, event-free survival, GATA1 mutation status, cytogenetics, and minimal residual disease results. Results.—Sixty myelodysplastic syndrome and 103 acute myeloid leukemia samples were reviewed. Both had distinctive features compared to those of patients without Down syndrome. They showed megakaryocytic and erythroid but little myeloid dysplasia, and marked megakaryocytic hyperplasia with unusual megakaryocyte morphology. In acute myeloid leukemia cases, megakaryoblastic differentiation of blasts was most common (54 of 103, 52%); other cases showed erythroblastic (11 of 103, 11%), mixed erythroid/megakaryoblastic (20 of 103, 19%), or no differentiation (10 of 103, 10%). Myelodysplastic syndrome and acute myeloid leukemia cases had similar event-free survival and overall survival. Leukemic subgroups showed interesting, but not statistically significant, trends for survival and minimal residual disease. Cases with institutional diagnoses of French American British M1-5 morphology showed typical features of Down syndrome disease, with survival approaching that of other cases. Conclusions.—Myelodysplastic syndrome and acute myeloid leukemia in Down syndrome display features that allow discrimination from standard cases of disease. These distinctions are important for treatment decisions, and for understanding disease pathogenesis. We propose specific diagnostic criteria for Down syndrome–related subtypes of acute myeloid leukemia and myelodysplastic syndrome.

Original languageEnglish (US)
Pages (from-to)466-472
Number of pages7
JournalArchives of Pathology and Laboratory Medicine
Volume144
Issue number4
DOIs
StatePublished - 2020

Fingerprint Dive into the research topics of 'Pathologic features of down syndrome myelodysplastic syndrome and acute myeloid leukemia a report from the Children’s Oncology Group protocol AAML0431'. Together they form a unique fingerprint.

  • Cite this

    Mast, K. J., Taub, J. W., Alonzo, T. A., Gamis, A. S., Mosse, C. A., Mathew, P., Berman, J. N., Wang, Y. C., Jones, H. M., Campana, D., Coustan-Smith, E., Raimondi, S. C., Hirsch, B., Hitzler, J. K., & Head, D. R. (2020). Pathologic features of down syndrome myelodysplastic syndrome and acute myeloid leukemia a report from the Children’s Oncology Group protocol AAML0431. Archives of Pathology and Laboratory Medicine, 144(4), 466-472. https://doi.org/10.5858/arpa.2018-0526-OA